anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: This scoping review aimed to give an overview of the existing literature about ultrasound-guided labeling techniques of human cadaver ligaments and tried to work out the possibilities of integrating ultrasound into dissection courses.
METHODS: A literature review was carried out on the 3rd of January 2023, with relevant studies discovered in the following databases: MEDLINE, EMBASE, CENTRAL, BIOSIS Previews and Web of Science Core Collection. Grey literature was also considered. The reference lists of all relevant papers were scanned. Only ultrasound studies on human cadaver ligaments were included. The included studies' general characteristics and ultrasound-guided approaches to label the ligaments were taken from them and examined.
RESULTS: The search found 8899 matches, but only 96 of them met the criteria. The transverse carpal ligament (15.62%) and the annular pulleys (19.79%) were the ligaments that had received the greatest research attention. Twenty-three studies are included in the methodological analysis. Both the marking substrate and the injected volume were diverse. Although 65% of the included studies achieved 100% accuracy using the ultrasound directed labeling approaches.
CONCLUSIONS: Ultrasound-guided labeling techniques achieve a high accuracy. Therefore, this methodology could be a potential teaching tool for students during the dissection course. But caution is advised in drawing general conclusions because of the small sample sizes and different methodologies in the studies. Future larger-scale research is necessary.
The invention belongs to the field of medicines, and concretely relates to an infantile exogenous cough treatment medicine. The medicine comprises 3g of Herbal Ephedrae, 5g of cassia twig, 3g of white peony root, 5g of Pingxia, 3g of Chinese magnoliavine, 5g of mulberry bark, 5g of dried orange peel, 5g of Poria cocos, 5g of licorice root and 5g of Rhizoma Atractylodis Macrocephalae. The above medicines are mixed and ground to form fine powder. An administration method of the medicine is characterized in that 1.5g of the medicine is administrated by a 1 year old child every day, 2g of the medicine is administrated by a 2-4 year old child every day, 4g of the medicine is administrated by a 5-8 year old child every day, 6g of the medicine is administrated by a 8-12 year old child every day, and 8g of the medicine is administrated by an above 12 year old child every day; the medicine is administrated with warm water after meal. The medicine is used for treating infantile exogenous coughs, and has the efficacies of exterior syndrome relieving, lung astringing, phlegm reducing and cough relieving. The medicine is used to clinically treat 35 patients, 34 patients are cured, and the result of one patient is not fed back.
Chronic, non-cancer pain may result from injury or illness, such as rheumatoid arthritis or osteoarthritis, which causes suffering and a reduction in the quality of life. Opioids, such as fentanyl, are beneficial as potent pain-relieving drugs in patients with continuous pain. This is an open-label, prospective study to assess the degree of pain control provided by treatment with fentanyl administered through the skin via adhesive patches ("transdermal system") for 28 days in patients with rheumatoid arthritis or osteoarthritis of the hip or knee, whose pain is inadequately controlled by other medications. During the first week of treatment, a prophylactic anti-nausea and vomiting agent will be given to patients to control these symptoms that can occur during opioid therapy. After 28 days, patients who do not respond adequately to treatment will be tapered off by gradually reducing the dose of fentanyl. Assessment of effectiveness will include a rating of pain control (excellent, good, moderate, poor, very poor), Pain Assessment Questionnaire, Quality of Life Questionnaire (SF-36), Health Assessment Questionnaire (HAQ), recording of the usage of any additional pain-relieving medications, and an evaluation of the anti-nausea and vomiting treatment. Safety evaluations include incidence of adverse events, and physical examinations. The study hypothesis is that patients with rheumatoid arthritis or osteoarthritis of the hip or knee whose pain is not adequately controlled by other medications will show an improvement in pain control after 28 days of treatment with the fentanyl transdermal system. Fentanyl transdermal patches to deliver from 25 micrograms/hr to 100 micrograms/hr, changed every 3 days, for 28 days; doses may be adjusted for adequate pain control, Anti-nausea tablets (Metoclopramide, 10 mg, 3 times/day) during first week. Paracetamol tablets (500mg) to supplement pain control.
OBJECTIVE: Postoperative delirium (POD) has become a critical challenge with severe consequences and increased incidences as the global population ages. However, the underlying mechanism is yet unknown. Our study aimed to explore the changes in metabolites in three specific brain regions and saliva of older mice with postoperative delirium behavior and to identify potential non-invasive biomarkers.
METHODS: Eighteen-month-old male C57/BL6 mice were randomly assigned to the anesthesia/surgery or control group. Behavioral tests were conducted 24 h before surgery and 6, 9, and 24 h after surgery. Complement C3 (C3) and S100 calcium-binding protein B protein (S100beta) levels were measured in the hippocampus, and a metabolomics analysis was performed on saliva, hippocampus, cortex, and amygdala samples.
RESULTS: In total, 43, 33, 38, and 14 differential metabolites were detected in the saliva, hippocampus, cortex, and amygdala, respectively. "Pyruvate" "alpha-linolenic acid" and "2-oleoyl-1-palmitoy-sn-glycero-3-phosphocholine" are enriched in one common pathway and may be potential non-invasive biomarkers for POD. Common changes were observed in the three brain regions, with the upregulation of 1-methylhistidine and downregulation of D-glutamine.
CONCLUSION: Dysfunctions in energy metabolism, oxidative stress, and neurotransmitter dysregulation are implicated in the development of POD. The identification of changes in the level of salivary metabolite biomarkers could aid in the development of noninvasive diagnostic methods for POD.
Will be subject to PD plus muscle belly compressions of the upper limbs for 10 sessions, one session a day from Monday to Friday, with a duration de 10 to 15 minutes per patient. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
A virtual private network connection method and a memory card device using the virtual private network connection method are provided. Firstly, a virtual private network connection application program is provided. Then, the virtual private network connection application program is loaded in a memory card device. Then, the memory card device is installed in a medical device. After the virtual private network connection application program is executed and the memory card device is connected to a virtual private network server according to a connection request, the data from the medical device is transmitted to the virtual private network server through the memory card device. In such way, the data will not be attacked by malware and stolen by a third-party manufacturer during the transmission process.
Methods of treating or preventing chemoresistance or relapse growth of cancer cells are provided. Methods of treating or preventing resistance to tyrosine kinase based chemotherapeutic treatment in hematologic and solid tumors are provided. BCR-ABL drug resistance in chronic myelogenous leukemia (CML) and models for conducting further study on the same are presented. The methods comprise administering a therapeutically effective amount of one or more SIRT 1  modulators to the cells or subject in need thereof. The methods may be administered in combination with, prior to or subsequent to chemotherapy or may be administered to counteract the effect of a spontaneous genetic mutation. Methods of using SIRT 1  inhibitors to treat or prevent insulin and transferrin-induced resistance are also presented. A novel cell model to study mechanisms of acquired chemoresistance is also provided.
This study aimed at determining the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products in two different ethnic groups. It is a laboratory-based research study, conducted in two different ethnic groups, with an open cross-over design, including 24 healthy non-smoking voluntary subjects, aged from 18 to 45 years. 12 subjects will be Caucasian and 12 subjects will be Asian. 8 test sessions per subject are included in the study. Foods are consumed in a random order according to a randomisation list. The impact of the ethnic group and the products will be determined.
BACKGROUND: A consensus has not been reached on the association between weight loss and survival outcomes in patients with heart failure (HF). This meta-analysis aimed to assess the association of weight loss with cardiovascular or all-cause mortality in patients with HF.
METHODS: Two authors independently searched the articles indexed in the PubMed and Embase databases up to May 7, 2023. Post hoc analysis of randomized controlled trials or observational studies that reported the utility of weight loss in predicting cardiovascular or all-cause mortality in patients with HF were included.
RESULTS: Thirteen studies reporting on 12 articles involving 26,164 patients with HF were included. A comparison of weight loss with stable weight showed that the pooled adjusted hazard ratio (HR) for all-cause mortality was 1.75 (95% confidence intervals [CI] 1.43-2.14). Subgroup analysis revealed that weight loss was associated with an increased risk of all-cause mortality, irrespective of whether patients were overweight/obese (HR 1.76; 95% CI 1.41-2.20) or not (HR 1.90; 95% CI 1.14-3.14). The pooled adjusted HR of cardiovascular mortality was 1.64 (95% CI 1.18-2.28) for patients with weight loss compared to those without.
CONCLUSIONS: Weight loss is associated with an increased risk of cardiovascular and all-cause mortality in patients with HF. Assessing weight changes can provide prognostic information for patients with HF.
The invention is directed to a newly discovered class of polynucleotide decoys that is capable of competitively inhibiting the binding of transcription factors to the X-box sequence. This binding is necessary for the expression of MHC-II genes. The invention is also directed to methods of preparing these polynucleotide decoys, and methods of use thereof. In particular, we have identified a class of polynucleotide decoys that mimic the X-Box of MHC-II and competitively bind the MHC-II transcription factor RF-X, resulting in the modulation of MHC-II antigen expression. Thus, the invention can be used to inhibit the expression of HLA molecules on the surface of donor cells or organs, in order to render them invisible to the host's immune system, or in methods of treating an individual with an autoimmune disease characterized by dysfunctional expression of an MHC class II antigen. Further, because of the role of RF-X in the expression of several viral proteins, the polynucleotide decoys of the invention can be used in methods of treating an individual infected with hepatitis B virus, or cytomegalovirus.
Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have \< 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
FIELD: AIDS treatment. SUBSTANCE: method consists in liberating patient of various viruses, including, and first of all, AIDS producing retrovirus (HIV), cells contaminated by these viruses, and associated microorganisms by means of plasmasorption using individually prepared for each patient immunoadsorbents which are enhanced by covalently bound glucoprotein isolated from human placenta and manifesting elevated affinity to AIDS retrovirus. Blood purification procedure involves plasmophoresis directly after plasmosorption while simultaneously replenishing blood plasma with equal volume (1000-1200 ml) of plasma substitute in the form of rheopolyglucin and once more applying plasma sorption using fresh immunosorbent. Blood purification procedures alternate with applying specific immunostimulation using autovaccine prepared in each separate case on the basis of UV inactivated blood culture from given patient. In the late phases of AIDS development, blood purification and specific immunostimulation using autovaccine are performed via replenishment of macrophages and helper T cells damaged under AIDS conditions by way of intracostal transplantation of umbilical cord blood from umbilical cord cut off upon childbirth, in which all necessary stem cells-hemoleucopoesis precursors are present. EFFECT: facilitated blood purification procedure.
Prior data suggest antibiotic starts for patients with normal vital signs are common and there does not appear to be harm associated with stopping antibiotics after only 1 or 2 days in patients with normal oxygen saturations. We therefore propose a pilot patient-level three-way randomized trial to determine the best way to operationalize professional society recommendations for post-prescription antibiotic reviews amongst patients started on antibiotics with a stated indication of pneumonia despite normal respiratory rates and oxygenation levels. If the patient's median respiratory rate and oxygen saturation is normal after 1-2 days of antibiotics they will be randomized to usual care versus a EHR-based best practice alert versus pharmacist outreach. The EHR-based best practice alert will highlight the patient's normal respiratory rate and oxygenation and encourage stopping antibiotics if there isn't another indication for antibiotics. Pharmacist outreach will involve contacting the responding clinician or attending physician to determine the working diagnosis, review the patient's vital signs, and to ask the team to consider stopping antibiotics if there are no clear indications for antibiotics. In all cases, the final decision on whether to stop or continue antibiotics will be up to the primary team. We will assess the impact of these post-prescription review strategies to decrease unnecessary antibiotic utilization on antibiotic utilization (antibiotic days and antibiotic-free days) compared to usual care. Safety outcomes will include time to discharge, readmissions, hospital-free days, and mortality. We will also assess for change in the primary outcome over time.
A novel dual targeting powder formulation with bimodal particle size distribution. The formulation targets both the nasal cavity and the lung by a single intranasal administration. The compositions can comprise a therapeutic agent, including tamibarotene, a retinoid derivative with broad-spectrum antiviral activity. Spray freeze drying (SFD) and spray drying (SD) techniques are employed to produce tamibarotene powder formulations with specific particle size using appropriate atomizing nozzles. Two formulations of different particle size are mixed to produce a single powder formulation with dual deposition characteristic in both the nasal and lung regions. The ratio of the aerosol deposition fractions in the nasal cavity and the deep lung region can be modified by varying the mixing ratio of SD tamibarotene powder.
The aim of the study is to develop an herbal gel based on Acmella oleracea and do a comparative analysis to evaluate the intensity of pain during the digital rectal examination comparing to lidocaine gel group and ultrasound gel group.

We are conducting a randomized, controlled, single-blind clinical trial of man undergoing to digital rectal examination, with 150 participants. Will be recruit at the Urologic Clinic of the Samuel Libânio Clinical Hospital and Urologic Clinic CISAMESP in Pouso Alegre. Participants divided into three groups, A. oleracea gel group, lidocaine gel group and ultrasound gel group. The digital rectal examination always performed by the same doctor, on the same position. A visual analogue scale (VAS) will be the standard method to evaluate the pain levels. The VAS will be explained to all patients, 0 = no pain and 10 = the most severe pain.
Chronic rhinosinusitis (CRS) is a persistent nasal and paranasal sinus mucosa inflammation comprising two phenotypes, namely CRS with nasal polyps (CRSwNP) and without (CRSsNP). CRSwNP can be associated with asthma and hypersensitivity to non-steroidal anti-inflammatory drug (NSAID) in a syndrome known as NSAID-exacerbated respiratory disease (N-ERD). Furthermore, CRS frequently intertwines with respiratory allergies. This study investigated levels of 33 different nasal and serum cytokines and phenotypic characteristics of peripheral blood mononuclear cells (PBMCs) within cohorts of CRS patients (n = 24), additionally examining the influence of comorbid respiratory allergies by mass cytometry. N-ERD patients showed heightened type 2 nasal cytokine levels. Mass cytometry revealed increased activated naive B cell levels in CRSwNP and N-ERD, while resting naive B cells were higher in CRSsNP. Th2a cell levels were significantly elevated in allergic subjects, but not in CRS groups. In conclusion, there are distinct immunological features in PBMCs of CRS phenotypes and allergy.
A variety of methods and arrangements for sharing medical data are described. In one aspect, one or more data streams are received from one or more medical imaging/sensing or other types of devices. Frames are obtained from the streams. In some embodiments, particular frames and/or parts of frames are selectively encrypted. The frames are transmitted to a remote device, where they are rendered and/or displayed at the remote device. In various embodiments, the frames of different streams are synchronized.
Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
The invention discloses an inflammation prophase chemotactic factor antagonistic peptide, a preparation method thereof, and an application thereof. The invention belongs to the technical field of genetic engineering. The antagonistic peptide amino acid sequence is represented by SEQ ID NO:1. The antagonistic peptide screening method comprises steps that: PBMC cells are stimulated by endotoxin, such that chemotactic factors are produced, the cells are centrifuged, a supernatant is collected, and the chemotactic factors are separated and purified; the cell supernatant is adopted as a target, phage dodecapeptide is combined with the target, the target is eluted by using an acidic eluent, screened phages are amplified; the screening step is carried out for 4 rounds, and amplification is not carried out in the fourth round; positive screening analysis is carried out upon the phages obtained from the fourth round, binding activity analysis, competitive inhibition analysis, chemotactic factor generation inhibition analysis are carried out, and positive monoclonal phages are screened; sequencing and sequence analysis are carried out upon positive monoclonal phage DNA, such that the inflammation prophase chemotactic factor antagonistic peptide is obtained. With the antagonistic peptide provided by the invention, the secretion of inflammation prophase chemotactic factors can be specifically blocked. The chemotactic factors have advantages of low cost, high specificity, clear efficacy, and the like. Also, the chemotactic factors are safe and reliable.
Exocrine pancreatic insufficiency (EPI) diagnosis can be challenging due to several reasons. First, the main symptoms of EPI such as diarrhea, loose stool, bloating or weight loss have low specificity because they could be associated with many other conditions such as IBS or celiac disease. Second, EPI could be found concomitantly as an exacerbating factor with other causes of diarrhea and bloating leading to incomplete treatment and increased patient dissatisfaction due to partial resolution of symptoms. Although the prevalence of EPI in general population is not well known, a recent population study in 914 patients from Norway showed up to 10% prevalence of EPI using the measurement of fecal elastase-1 level in elderly. In another study, the prevalence of EPI diagnosed by low fecal elastase-1 in 314 patients with chronic diarrhea who satisfied the Rome II criteria for irritable bowel syndrome diarrhea (IBS-D) was 6.1%.Furthermore, an EPI prevalence of 4.4% (diagnosed by low fecal elastase-1) was documented in 90 patients who had serological and histological evidence of celiac disease. Interestingly, MRI was normal in all patients diagnosed with EPI in this study.

The gold standard tests for diagnosing EPI is three-day fecal fat quantification and determination of the coefficient of fat absorption. The patient is required to keep an intake of 100g of fat for five days and then collect feces for a time period of three days. Direct measurement of pancreatic function test with secreting stimulation is another sensitive test. . However these tests are cumbersome to apply to large number of patients with common complaints. Spot fecal elastase-1 measurement using enzyme linked immunosorbent assay (ELISA) has been shown to be highly sensitive and specific in diagnosing moderate to severe chronic pancreatitis in several studies. The favorable operating characteristics combined with the ease of using of the test makes it a good initial screening test for EPI.

Our preliminary data indicate that a large proportion (10 %) of patients with undiagnosed bloating and or diarrhea have EPI initially detected by low fecal elastase-1 and subsequently confirmed with Endoscopic Ultrasound and or direct measurement of pancreatic function tests. Therefore, Investigators propose to test the hypothesis that including fecal elastase-1 as part of the initial work-up for patients presenting with diarrhea and or bloating will identify patients who are confirmed EPI and may benefit from pancreatic enzyme replacement therapy and limit further unnecessary work up.
Children allocated to the study group will receive the same selected physical therapy program given to the control group for 45 minutes in addition to 45 minutes task-oriented circuit training program. The frequency of the whole program will be three times per week, for three months.
<P>PROBLEM TO BE SOLVED: To provide a food product for ameliorating constipation, derived from a natural product, and having a high constipation-ameliorating activities by using lactic acid bacteria, especially deactivated lactic acid bacteria.  <P>SOLUTION: This food product for ameliorating the constipation contains killed lactic acid bacteria (e.g. Enterococcus faecalis). The constipation-ameliorating food product containing the killed lactic acid bacteria, at least one of a vegetable fiber, an oligosaccharide and aloe, and a pasted product of a kale (Brussicaoleracea L var acephala) is cited as an example. The use of the killed lactic acid bacteria enables the food product containing the kale added with the lactic acid bacteria to be produced. The obtained food product is excellently safe and has excellent constipation-ameliorating activities, properties of which are superior ones.  <P>COPYRIGHT: (C)2004,JPO